Dear Editor,
We would like to thank Prof. Viroj Wiwanitkit for his interest in our study [1] . Lazzarotto et al. [2] stated that: 'If determination of the anti-CMV antibody avidity is carried out early (before 18 weeks), it can identify all pregnant women who will transmit congenital CMV infection to their offspring. Moreover, if determination of avidity index is carried out later on during pregnancy, 60% of women who will transmit the infection still have antibody with low avidity, while the others will develop moderate or high avidity. ' We could not find the English version of the relatively old report from Lafarga et al. [3] , and the method used for the IgG avidity analysis was not clarified. In recent years, many new fully automated assays with high sensitivities and specificities have been developed by different manufacturers; for example, Abbott uses a chemiluminescent microparticle immunoassay (CMIA) performed on the ARCHITECT [4] , BioMérieux uses an enzymelinked fluorescent assay (ELFA) performed on the VIDAS, and DiaSorin uses a chemiluminescence immunoassay (CLIA) performed on the LIAISON analyzer.
In our study, we used the VIDAS CMV-IgG avidity assay. In a recent report by Vauloup-Fellous et al. [5] , they suggested 'new VIDAS cut-off values of 0.40 for low avidity and 0.65 for high avidity, which significantly increase the test performance and enable better patient managements'. Also, they 'demonstrated that the VIDAS CMV-IgG avidity assay allows observing correctly the maturation of CMV-IgG avidity, which could be useful as an additional parameter for diagnosis of a recent CMV infection'.
Lumley et al. [6] recently reported that pregnant women with positive IgM and low/equivocal avidity testing on the Abbott AR-CHITECT and DiaSorin LIAISON assays persisted over 18 weeks and therefore they may not have had primary infections. They suggested that a larger series of patients should be examined to determine how frequently this phenomenon occurs. 
